Biofortis
Addison, Illinois, 60101, United States
NCT Number: NCT04619875
This exploratory, randomized, open label study aims to explore the safety, tolerability, pharmacokinetics, and effects of increasing intake amounts of two novel glycans on the gut microbiota of healthy subjects.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Addison, Illinois, 60101, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
To be eligible for inclusion, the patient must fulfill all of the following criteria at screening:
Patients will be excluded from the study if they meet any of the following criteria at screening:
KB5, a novel glycan, is a Kaleido laboratory code for KB174
SG1 is a novel glycan
Lactulose is a synthetic dissacharide
Time frame: Day -8 to Day 35
Time frame: Day -8 to Day 35
The GITQ is an assessment of the frequency and severity of GI symptoms, eg., gas, abdominal pain, calculated on a scale from 0 (None/Not applicable) to a maximum score of 60 (Severe/Much more than usual) for all questions
Time frame: Day -8 to Day 35
The BSS is an assessment of stool consistency on a scale from 1 (separate hard lumps, like nuts, hard to pass) through 7 (watery, no solid pieces, entirely liquid)
Kaleido Biosciences
Industry
A Randomized, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of Increasing Intake Amounts of Two Novel Glycans on the Gut Microbiota of Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details